We report the integrated proviral LTR sequence variation in four patients on highly active antiretroviral therapy (HAART). Integrated proviral fragments of LTR taken from four time points were PCR amplified from PBMCs and 10 to 12 individual clones were sequenced for each time point. Intrasample genetic distances and phylogenetic reconstruction of all LTR sequences demonstrated that 1-2 years of successful HAART did not significantly reduce the genetic repertoire of the integrated reservoir of HIV-1.
A latent replication-competent integrated HIV-1 reservoir persists in resting CD4 T lymphocytes of infected individuals despite prolonged plasma virus suppression by successful antiretroviral combination therapy (3, 8, 21) . Moreover, a very slow or no reduction in this latently infected reservoir has been documented after a long period of plasma virus suppression (7, 11, 16, 17) . Low levels of ongoing viral replication have been correlated with the slow decay of the HIV-1 latent reservoir (5, 9, 10, 14, 18, 23) . The stability of this HIV-1 latent reservoir has been also associated with the long life of latently infected cells (7, 16, 23) .
Since the current antiretroviral agents are ineffective at eliminating latent forms of HIV-1, this latent viral reservoir remains a major obstacle to virus eradication in infected individuals (2) . Therefore, extensive efforts are being made to further characterize this virus reservoir. To investigate whether a long period of successful therapy affects the genetic composition of this virus reservoir, we have studied the integrated proviral long terminal repeat (LTR) sequence variation in four patients on highly active antiretroviral therapy (HAART) who had had undetectable levels of HIV-1 RNA for 48 weeks or more.
By measuring over time levels of total and integrated cell-associated viral DNA we have previously investigated the reservoir of HIV-1 present in peripheral blood mononuclear cells (PBMCs) of 10 drug-naïve HIV-1-infected patients who started HAART (11) . Four patients (B, C, D, and H) from the former report were selected for this study. Patients B, D, and H were treated with 3TC, D4T, and ritonavir. Patient C was treated with 3TC, D4T, and indinavir. Patients B, C, and H were selected on the basis of their treatment compliance and continued suppression of plasma HIV-1 RNA (Ͻ20 copies/ml). Patient D was selected because therapy was stopped after 70 weeks of treatment and a plasma viral rebound was detected at week 72. Patient D resumed therapy (3TC, D4T, nevirapine, and nelfinavir) at week 93 and showed again an undetectable plasma viral load at week 108 (Fig. 1) . Blood CD4 T cell counts and HIV-1 RNA and DNA profiles of study individuals are shown in Fig. 1 .
To assess the evolution of genetic diversity during successful therapy, the HIV-1 integrated LTR provirus sequence variation in the PBMCs from these four individuals (B, C, D, and H) was analyzed. Integrated proviral fragments of LTR taken from four time points were PCR amplified from PBMCs. The study period included a naïve phase and 1-2 years of therapy (sampling times are given in Table 1 ). Population-based sequencing of the proviral HIV-1 pol region of samples recovered after 108 weeks of therapy did not show amino acid substitutions associated with drug resistance in any of the four patients studied (data not shown). Diversity in the integrated LTR sequence was quantitatively evaluated for each patient by computing the intra-time-point genetic distances derived from individual LTR molecular clones from the four time points studied ( Table 1 ). The mean intrasample DNA genetic distances at the beginning of treatment were 2.3, 2.7, 1.1, and 3.4% for patients B, C, D, and H, respectively (Table 1) . After 48 weeks (32 weeks for patient C) of therapy no significant reduction in the intrasample genetic distances was noted (2.2, 2.6, 0.6, and 3.2%, respectively) compared to the baseline values.
Furthermore, samples collected between 48 and 108 weeks of therapy had very similar genetic diversity (2.6, 3.2, 0.9, and 3.1%, respectively) compared with the corresponding baseline or 48-week samples (Table 1) . Of note, patient D, who stopped therapy at week 70 and in which a rebounding plasma viral RNA was detected at week 72 ( Fig. 1) , showed a genetic diversity in the former rebounding viral RNA population (1.7%) similar to that found in the baseline integrated HIV-1 proviral DNA (Table 1). Phylogenetic reconstruction of all LTR sequences revealed, for each patient, an intermingling of sequences from the four time points, that is, distinct, temporal clustering of sequences at each time point was not observed (Fig. 2) . This pattern is indicative of absence of genetic change in this locus during the time period analyzed. Interestingly, the patient D rebounding viral RNA population clustered distinctly and was closely associated with one proviral DNA clone isolated before the beginning of therapy (Fig. 2) . Nevertheless, the low viral genetic diversity and bootstrap proportions (lower than 50-100 replicates) (Fig. 2) observed within patient D did not allow us to extract any conclusion about the origin of the rebounding viral RNA detected in this patient as has been recently shown in other cohorts of patients that interrupted HAART (1, 22) . Taken together, these results demonstrate that 2 years of successful HAART does not significantly reduce the genetic repertoire of the integrated reservoir of HIV-1 DNA present in latently infected CD4 T cells.
Several recent reports have stressed the stability of the HIV-1 latent reservoir after successful combination therapy (7, 11, 16, 17, 18 ). Here we show that accompanying its size stability the HIV-1 latent reservoir maintains almost intact its genetic repertoire. These findings are in FIG. 1 . Summary of CD4 T cell counts and levels of HIV-1 DNA and virion-associated RNA for each of the four patients (B, C, D, and H). The time after the beginning of the therapy is annotated on the abscissa. CD4 T cell counts were measured by flow-activated cytometric assay and expressed per microliter of blood. HIV-1 RNA levels were measured by a quantitative reverse transcription-PCR assay (Roche) and are expressed per milliliter of plasma. Total and integrated HIV-1 DNA copy numbers were calculated by quantitative nested PCR as described previously (11) and are expressed per 10 6 PBMCs. The times in weeks at which sequencing was performed are indicated in Table 1 . Specific antiretroviral therapies are described in the text.
agreement with a recent study in which drug-resistant virus selected by previous nonsuppressive therapy persists for long periods of time in latently infected resting CD4 T cells of children treated with a suppressive regimen (16) . Similarly, an early study found that HIV-1 sequences present before seroconversion may reappear
FIG. 2.
Neighbor-joining phylogram of integrated proviral LTR sequences from PBMCs of the four patients analyzed in this study. The 72-week patient D plasma HIV-1 RNA population is also shown (green circles). Phylogenetic reconstruction of all LTR sequences showed that clones clustered in a patient-specific manner, indicating the absence of PCR product cross-contamination. Phylogenetic reconstruction of all viral sequences from the four patients was generated by using the Kimura two-parameter distance matrix fed into a neighbor-joining tree construction algorithm (6) . Numbers at branch nodes refer to the number of bootstrap repetitions (of 100) at which the distal sequences grouped together; only those greater than 50% are shown. The times in weeks at which sequencing was performed are indicated in Table 1 . Five sequences from patient B (AF294045, AF294051, AF294053, AF294056, and AF294071) and one from patient D (AF294169) containing hypermutations (15) were not included in the analysis. several years later (13) , further emphasizing the genetic stability of the HIV-1 latent reservoir.
Our findings indicate that the current antiretroviral therapies are ineffective at reducing the HIV-1 latent genetic repertoire. Therefore, treatment with suppressive protocols that include immune stimulation or structured interruption of therapy have to take into account that the virus population that will emerge may contain their entire repertoire of variants (drug-resistant mutants or syncytium-inducing viruses, etc.) present before the beginning of the therapy.
Materials and Methods. Patients.
Four drug-naïve HIV-1-seropositive patients who started a triple combination therapy were selected for this study. Patients B, D, and H were treated with 3TC, D4T, and ritonavir. Patient C was treated with 3TC, D4T, and indinavir (11) . Blood CD4 T cell counts and HIV-1 RNA and DNA levels are shown in Fig. 1 . Plasma HIV-1 RNA levels were measured by the Amplicor monitor assay (Roche). Total and integrated HIV-1 DNA quantification was performed by end-point limiting dilution, as described previously (11) .
Recovery and Analysis of DNA and RNA Sequences.
We tracked the HIV-1 integrated provirus sequence variation in the PBMCs obtained from sequential blood samples from three patients (B, C, and H) that were able to maintain undetectable levels of plasma HIV-1 RNA (below 20 copies/ml) (Fig. 1) for 108 weeks and from another patient (D) who stopped treatment after 70 weeks of therapy. Genomic PBMC DNA purification and PCR amplification were performed as described previously (11) . To specifically amplify integrated DNA we used an oligonucleotide (Alu-LTR 5Ј) designed to amplify cellular Alu repeat sequences (19) . Sequences of the oligonucleotides used are Alu-LTR 5Ј, 5Ј-TC-CCAGCTACTCGGGAGGCTGAGG-3Ј (nt 164 to 187 of the Alu consensus sequence (12) , and Alu-LTR 3Ј, 5Ј-AGGCAAGCTTTATTGAGGTTAAGC-3Ј (HIV-1 HXB2 positions 516 to 540). For the nested PCR oligonucleotides NI-2 5Ј, 5Ј-CACACACAAGGCTACTTCCCT-3Ј (HIV-1 HXB2 positions 57 to 77), and NI-2 3Ј, 5Ј-GC-CACTCCCCIGTCCCGCCC-3Ј (HIV-1 HXB2 positions 389 to 408), described by Chun et al. (3) , were used. End-point dilution of PBMC DNA was performed before nested PCR to make products derived from a single provirus. For each sample at least 10 amplicons were directly sequenced with a 310 automated sequencer and dRhodamine chain terminator chemistry (Applied Biosystems). The 72-week patient D plasma sample was processed for RNA extraction as previously described (14) . The viral RNA was retrotranscribed into cDNA with oligonucleotide NI-2 3Ј. cDNA was PCR amplified with oligonucleotides NI-2 5Ј and NI-2 3Ј, followed by a second round of amplification with oligonucleotides NI-3 5Ј, 5Ј-TGGCAGAACTACA-CACCAGG-3Ј (HIV-1 HXB2 positions 81 to 100), and NI-3 3Ј, 5Ј-GAAAGTCCCCAGCGGAAAGTCCC-3Ј (HIV-1 HXB2 positions 350 to 372). As for the PBMC samples, end-point dilution of the cDNA was performed before nested PCR. The sequencing oligonucleotide was NI-3 5Ј. Sequences were aligned using CLUSTAL W (20) . Pairwise nucleotide distances (excluding gaps in the pairwise alignment) were calculated with the Kimura two-parameter model of evolution with a transition/ transversion ratio of 2 as implemented in WET (4). Phylogenetic reconstructions were generated by using the neighbor-joining method included in the PHYLIP software package (6) . The distribution of nucleotide distances for each patient time point was subjected to nonparametric statistical treatment by using the Wilcoxon signed rank test included in the SPSS version 7.5 software package.
Nucleotide Sequence Accession Numbers. The nucleotide sequence data reported in this paper have been submitted to the GenBank database under Accession No. AF294033 to AF294223.
ACKNOWLEDGMENTS
Financial support to A. Ibá ñez was granted by Fundació irsiCaixa. This work was supported in part by grants from Fundació irsiCaixa and FIS (98/0054-03). 
